Tacrolimus and minidose methotrexate for prevention of acute graft- versus-host disease after matched unrelated donor marrow transplantation

Blood

Volumn 88, Issue 11, 1996, Pages 4383-4389

  Przepiorka, Donna ^a   Ippoliti, Cindy ^b   Khouri, Issa ^b   Woo, Michael ^b   Mehra, Rakesh ^b   Le Bherz, Donna ^b   Giralt, Sergio ^b   Gajewski, James ^b   Fischer, Harald ^b   Fritsche, Herbert ^b   Deisseroth, Albert B ^b   Cleary, Karen ^b   Champlin, Richard ^b   Van Besien, Koen ^b   Andersson, Borje ^b   Maher, Rochelle ^b   Fitzsimmons, William ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CREATININE; CYCLOPHOSPHAMIDE; METHOTREXATE; TACROLIMUS; THIOTEPA;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DONOR; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LYMPHOMA; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; SURVIVAL TIME;

EID: 10544224147     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.11.4383.bloodjournal88114383     Document Type: Article

References (53)

1. Beatty PG, Hansen JA, Longton GM, Thomas ED, Sanders JE, Martin PJ, Bearman SI, Anasetti C, Petersdorf EW, Mickelson EM, Pepe MS, Appelbaum FR, Buckner CD, Clift RA, Petersen FB, Stewart PS, Storb RF, Sullivan KM, Tesler MC, Witherspoon RP: Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 51:443, 1991
2. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, McGlave P, Perkins HA, Phillips GL, Sanders J, Stroncek D, Thomas ED, Blume KG: Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328:593, 1993
3. Downie TR, Hows JM, Gore SM, Bradley BA, Howard MR: A survey of use of unrelated volunteer donor bone marrow transplantation at 46 centres worldwide, 1989-1993. Bone Marrow Transplant 15:499, 1995
4. Dini G, Lanino E, Lamparelli T, Barbanti M, Sacchi N, Carcassi C, Locatelli F, Porta F, Rosti G, Alessandrino EP, Aversa F, Marenco P, Guidi S, Uderzo C, Amoroso A, Di Bartolomeo P, Garbarino L, La Nasa G, Rosetti F, Miniero R, Soligo D, Manfredini L, Bacigalupo A: Unrelated donor marrow transplantation: inital experience of the Italian Bone Marrow Transplant Group (GITMO). Bone Marrow Transplant 17:55, 1996
5. Beatty PG, Ash R, Hows JM, McGlave PB: The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: Experience of four marrow transplant centers. Bone Marrow Transplant 4:287, 1989
6. Schiller G, Feig SA, Territo M, Wolin M, Lill M, Belin T, Hunt L, Nimer S, Champlin R, Gajewski J: Treatment of advanced acute leukemia with allogeneic bone marrow transplantation from unrelated donors. Br J Haematol 88:72, 1994
7. Bearman SI, Mori M, Beatty PG, Meyer WG, Buckner CD, Peteren FB, Sanders JE, Anasetti C, Martin P, Appelbaum FR, Hansen JA: Comparison of morbidity and mortality after marrow transplantation from HLA-genotypically identical siblings and HLA-phenotypically identical unrelated donors. Bone Marrow Transplant 13:31, 1994
8. Ochs L, Shu XO, Miller J, Enright H, Wagner J, Filipovich A, Miller W, Weisdorf D: Late infections after allogeneic bone marrow transplantation: Comparison of incidence in related and unrelated donor transplant recipients. Blood 86:3979, 1995
9. Davies SM, Ramsay NKC, Haake RJ, Kersey JH, Weisdorf DJ, McGlave PB, Blazar BR: Comparison of engraftment in recipient of matched sibling or unrelated donor marrow allografts. Bone Marrow Transplant 13:51, 1994
10. Hessner MJ, Endean DJ, Casper JT, Horowitz MM, KeeverTaylor CA, Roth M, Flomenberg N, Drobyski WR: Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 86:3987, 1995
11. McGlave PB, Beatty P, Ash R, Hows JM: Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: Results in 102 cases. Blood 75:1728, 1990
12. Phillips GL, Barnett MJ, Brain MC, Chan KW, Huebsch LB, Klingemann HG, Meharchand J, Reece DE, Rybka WB, Shepherd JD, Spinelli JJ, Walker IR, Messner HA: Allogeneic bone marrow transplantation using unrelated donors: A pilot study of the Canadian Bone Marrow Transplant Group. Bone Marrow Transplant 8:477, 1991
13. Belanger C, Esperou-Bourdeau H, Bordigoni P, Jouet JP, Souillet G, Milpied N, Troussard X, Kuentz M, Herve P, Reiffers J, Demeocq F, Dauriac C, Biaise D, Michallet M, Fiere D, Freycon F, Gratecos N, Rio B, Leblond V, Ifrah N, Attal M, Bergerat JP, Vilmer E, Pico J, Raffoux C, Caudrelier P, Gluckman E: Use of an antiinterleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplant 11:293, 1993
14. Gajewski JL, Ho WG, Feig SA, Hunt L, Kaufman N, Champlin RE: Bone marrow transplantation using unrelated donors for patients with advanced leukemia or bone marrow failure. Transplantation 50:244, 1990
15. Leelasiri A, Greer JP, Stein RS, Goodman S, Brandt SA, Edwards JR, Wolff SN: Graft-verusus-host disease prophylaxis for matched unrelated donor bone marrow transplantation: Comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone. Bone Marrow Transplant 15:401, 1995
16. Nademanee A, Schmidt GM, Parker P, Dagis AC, Stein A, Snyder DS, O'Donnell M, Smith EP, Stepan DE, Molina A, Wong KK, Margolin K, Somlo G, Littrell B, Woo D, Sniecinski I, Niland JC, Forman SJ: The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 86:1228, 1995
17. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H: FK506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 40:129, 1987
18. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H, Ochiai T: FK506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK506 in vitro. J Antibiot 40:1256, 1987
19. Bierer BE: Immunosuppressive agents targeting T-cell activation pathways, in Przepiorka D (ed): Recent Developments in Transplantation Medicine, vol 1. New Immunosuppressive Drugs. Glenview, IL, Physicians & Scientists, 1995, p 9
20. Przepiorka D: Tacrolimus: preclinical and clinical experience, in Przepiorka D (ed): Recent Developments in Transplantation Medicine, vol 1. New Immunosuppressive Drugs. Glenview, IL, Physicians & Scientists, 1995, p 29
21. Markus PM, Cai X, Ming W, Demetris AJ, Fing JJ, Starzl TE: FK506 reverses acute graft-verus-host disease after allogeneic bone marrow transplantation in rats. Surgery 110:357, 1991
22. Markus PM, Cai X, Ming W, Demetris AJ, Fing JJ, Starzl TE: Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation 52:590, 1991
23. Storb R, Raff RF, Appelbaum FR, Deeg HJ, Fitzsimmons W, Graham TC, Pepe M, Pettinger M, Sale G, van der Jagt R, Schuening FG: FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. Transplantation 56:800, 1993
24. Tzakis AG, Abu-Elmagd K, Fung JJ, Bloom EJ, Nour B, Greif F, Starzl TE: FK506 rescue in chronic graft-versus-host disease after bone marrow transplantation. Transplant Proc 23:3225, 1991
25. Masaoka T, Shibata H, Kakishita E, Kanamaru A, Takemoto Y, Moriyama Y: Phase II study of FK506 for allogeneic bone marrow transplantation. Transplant Proc 23:3228, 1991
26. Kanamaru A, Takemoto Y, Kakishita E, Dohy H, Kodera Y, Moriyama Y, Shibata A, Kasai M, Katoh S, Saitoh H, Matsuda T, Hattori M, Okamoto S, Asano S, Horiuchi A, Harada M, Hiraoka A, Masaoka T: FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporine and/or other immunosuppressants. Bone Marrow Transplant 15:885, 1995
27. Koehler MT, Howrie D, Mirro J, Neudorf S, Blatt J, Corey S, Wollman M, Kelly-Ekeroth V, Reyes J: FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. Bone Marrow Transplant 15:895, 1995
28. Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C, Appelbaum FR, Doney K, Martin P, Slattery J, Sullivan K, van der Jagt R, Witherspoon R, Jusko WJ, Zager RA, Deeg HJ: Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study. Blood 85:3746, 1995
29. Fay JW, Wingard JR, Antin JH, Collins RH, Pineiro LA, Balzar BR, Saral R, Bierer BE, Przepiorka D, Fitzsimmmons WE, Are RM, Weisdorf DJ: FK506 monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 87:3514, 1996
30. Park MS, Tonai R: Phenotype frequencies of the Class II DNA alleles by the patterns of sequence specific primer mixtures: Population studies and probable haplotypes, in Terasaki PI, Cecka JM (eds): Clinical Transplants 1992. Los Angeles, CA, UCLA Tissue Typing Lab, 1992, p 475
31. Przepiorka D, Ippoliti C, Giralt S, van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna M, Cork A, Lee M, Estey E, Andreeff M, Champlin R: A Phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant 14:449, 1994
32. Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, Andersson BS, van Besien KW, Mehra RC, Giralt S, Ippoliti C, Marshall M, Thomas MW, O'Brien S, Robertson LE, Deisseroth AB, Champlin RE: Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: Preliminary results. J Clin Oncol 12:748, 1994
33. Grenier FC, Luczkiw J, Bergmann M, Lunetta S, Morrison M, Blonski D, Shoemaker K: A whole blood FK506 assay for the IMx analyzer. Transplant Proc 23:2748, 1991
34. Snover DC: Biopsy interpretation in bone marrow transplantation, in Rosen PP, Fechner RE (eds): Pathology Annual, Part 2. Hartford, CT, Appleton & Lange, 1989, p 63
35. Przepiorka D, Weisdorf D, Martin P, Klingmann H, Beatty P, Hows J, Thomas ED: Report of the 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825, 1995
36. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562, 1988
37. Yam P, Petz LD, Ali S, Stock AD, Wallace RB: Development of a single probe for documentation of chimerism following bone marrow transplantation. Am J Hum Genet 41:867, 1987
38. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
39. Khouri IF, Ippoliti C, Gajewski J, Przepiorka D, Champlin RE: Neutropenia following allogeneic bone marrow transplantation: Response to therapy with high dose intravenous immunoglobulin. Am J Hematol 52:313, 1996
40. Petersdorf EW, Longton GM, Anasetti C, Martin PJ, Mickelson EM, Smith AG, Hansen JA: The significance of HLA-DRBI matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 86:1606, 1995
41. Przepiorka D, Dimopoulos M, Smith T, lppoliti C, Diener K, Luna M, Champlin RE. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for marrow transplantation: Risk factors for early regimen-related toxicities. Ann Hematol 68:183, 1994
42. Japanese FK506 Study Group: Japanese study of FK506 on kidney transplantation: The benefit of monitoring the whole blood FK506 concentration. Transplant Proc 23:3085, 1991
43. Winkler M, Jost U, Ringe B, Gubematis G, Wonigeit K, Pichlmayr R: Association of elevated FK506 plasma levels with nephrotoxicity in liver-grafted patients. Transplant Proc 23:3153, 1991
44. Iwasaki K, Matsuda H, Nagase K, Shiraga J, Tokuma Y, Uchida K: Effect of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res Comm Chem Pathol Pharmacol 82:209, 1993
45. Assan R, Fredj G, Larger E, Feutren G, Bismuth H: FK506/fluconazole interaction enhances FK506 nephrotoxicity. Diabetes Metab 20:49, 1994
46. Deeg HJ, Storb R, Weiden PL, Raff RF, Sale GE, Atkinson K, Graham TC, Thomas ED: Cyclosporin A and methotrexate in canine marrow transplantation: Engraftment, graft-versus-host disease and induction of tolerance. Transplantation 34:30, 1982
47. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J, Hill R, Longton G, Lum L, Martin P, McGuffin R, Sanders J, Singer J, Stewart P, Sullivan K, Witherspoon R, Thomas ED: Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 68:119, 1986
48. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986
49. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C, Appelbaum FR, Bowden RA, Deeg HJ, Doney K, Martin PJ, Sullivan KM, Sanders J, Witherspoon RP: Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 80:1838, 1992
50. Yau JC, Dimopoulos MA, Huan SD, Spencer V, Woo SY, Spitzer G, Brunner LJ, Wallerstein RO, Deisseroth AB, Andersson BS, LeMaistre CF: An effective acute graft-vs-host disease prophylaxis with minidose methotrexate, cyclosporine and single-dose methylprednisolone. Am J Hematol 38:288, 1991
51. Giralt SA, Vriesendorp HM, Andersson BS, van Besien K, Dimopoulos M, Mehra R, Przepiorka D, Khouri I, Yau J, LeMaistre CF, Kantarjian H, Deisseroth AB, Chamnplin RE. Etoposide, cyclophosphamide, total body irradiation and allogeneic bone marrow transplantation: An effective treatment for hematologic malignancies. J Clin Oncol 12:1923, 1994
52. Wingard JR, Nash RA, Ratanatharathorn V, Fay JW, Klein JL, Przepiorka D, Devine SM, Fitzsimmons WE: Lack of interaction between tacrolimus (FK506) and methotrexate (MTX) in bone marrow transplant (BMT) recipients. Blood 86:396a, 1995 (abstr, suppl 1)
53. Przepiorka D, Ippolitti C, Khouri I, Stein L, van Besien K, Mehra R, Giralt S, Gajewski J, Fritsche H, Deisseroth AB, Cleary K, Andersson B, Champlin R: Tacrolimus and mini-methotrexate vs T-cell depletion, cyclosporine and immunotoxin for prevention of acute graft-vs-host disease (GVHD) after HLA-nonidentical marrow transplantation. Blood 86:621a, 1995 (abstr, suppl 1)